RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Huan Xie and Dong Liang.
Connection Strength

3.142
  1. Wang Y, Ma J, Lin SY, Xie H, Liang D. A stability indicating LC-MS/MS method for quantification of a NOX Inhibitor R14 in its bisulfite adduct form for pharmacokinetic studies. J Pharm Biomed Anal. 2023 May 10; 228:115326.
    View in: PubMed
    Score: 0.226
  2. Sarkar M, Wang Y, Ekpenyong O, Liang D, Xie H. Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 03; 15(2):e1846.
    View in: PubMed
    Score: 0.217
  3. Wang Y, Xie H, Alugubelli YR, Ma Y, Xu S, Ma J, Liu WR, Liang D. Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MPI8, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies. Pharmaceuticals (Basel). 2022 May 27; 15(6).
    View in: PubMed
    Score: 0.214
  4. Rincon Nigro ME, Du T, Gao S, Kaur M, Xie H, Olaleye OA, Liang D. Metabolite Identification of a Novel Anti-Leishmanial Agent OJT007 in Rat Liver Microsomes Using LC-MS/MS. Molecules. 2022 Apr 30; 27(9).
    View in: PubMed
    Score: 0.213
  5. Chen Y, Gao X, Gupta R, Ma J, Dere R, Liang D, Xie H. Development and Validation of an LC-MS/MS Method for AC1LPSZG and Pharmacokinetics Application in Rats. J Chromatogr Sci. 2022 Jan 01; 60(1):26-34.
    View in: PubMed
    Score: 0.208
  6. Gao X, Tsai RYL, Ma J, Wang Y, Liu X, Liang D, Xie H. Determination of Oxaliplatin by a UHPLC-MS/MS Method: Application to Pharmacokinetics and Tongue Tissue Distribution Studies in Rats. Pharmaceuticals (Basel). 2021 Dec 31; 15(1).
    View in: PubMed
    Score: 0.208
  7. Rincon Nigro M, Ma J, Awosemo OT, Xie H, Olaleye OA, Liang D. Development and Validation of a Sensitive, Specific and Reproducible UPLC-MS/MS Method for the Quantification of OJT007, A Novel Anti-Leishmanial Agent: Application to a Pharmacokinetic Study. Int J Environ Res Public Health. 2021 04 27; 18(9).
    View in: PubMed
    Score: 0.198
  8. Gao X, Wu L, Tsai RYL, Ma J, Liu X, Chow DS, Liang D, Xie H. Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid. Pharmaceutics. 2021 Apr 17; 13(4).
    View in: PubMed
    Score: 0.198
  9. Ekpenyong O, Cooper C, Ma J, Guy NC, Payan AN, Ban F, Cherkasov A, Cox MB, Liang D, Xie H. Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer. Pharmaceuticals (Basel). 2020 Nov 13; 13(11).
    View in: PubMed
    Score: 0.192
  10. Wang Y, Ma J, Martinez ED, Liang D, Xie H. A UHPLC-MS/MS method for the quantification of JIB-04 in rat plasma: Development, validation and application to pharmacokinetics study. J Pharm Biomed Anal. 2020 Nov 30; 191:113587.
    View in: PubMed
    Score: 0.189
  11. Ekpenyong O, Gao X, Ma J, Cooper C, Nguyen L, Olaleye OA, Liang D, Xie H. Pre-Clinical Pharmacokinetics, Tissue Distribution and Physicochemical Studies of CLBQ14, a Novel Methionine Aminopeptidase Inhibitor for the Treatment of Infectious Diseases. Drug Des Devel Ther. 2020; 14:1263-1277.
    View in: PubMed
    Score: 0.184
  12. Gao X, Tsai RYL, Ma J, Bhupal PK, Liu X, Liang D, Xie H. Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jan 01; 1136:121930.
    View in: PubMed
    Score: 0.180
  13. Ekpenyong O, Cooper C, Ma J, Liang D, Olaleye O, Xie H. A simple, sensitive and reliable LC-MS/MS method for the determination of 7-bromo-5-chloroquinolin-8-ol (CLBQ14), a potent and selective inhibitor of methionine aminopeptidases: Application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 15; 1097-1098:35-43.
    View in: PubMed
    Score: 0.165
  14. Liang S, Bian X, Liang D, Sivils JC, Neckers LM, Cox MB, Xie H. Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol. 2016; 21(1):121-6.
    View in: PubMed
    Score: 0.127
  15. Liang S, Sanchez-Espiridion B, Xie H, Ma J, Wu X, Liang D. Determination of proline in human serum by a robust LC-MS/MS method: application to identification of human metabolites as candidate biomarkers for esophageal cancer early detection and risk stratification. Biomed Chromatogr. 2015 Apr; 29(4):570-7.
    View in: PubMed
    Score: 0.125
  16. Bian X, Liang S, John J, Hsiao CH, Wei X, Liang D, Xie H. Development of PLGA-based itraconazole injectable nanospheres for sustained release. Int J Nanomedicine. 2013; 8:4521-31.
    View in: PubMed
    Score: 0.119
  17. John MK, Xie H, Bell EC, Liang D. Development and pharmacokinetic evaluation of a curcumin co-solvent formulation. Anticancer Res. 2013 Oct; 33(10):4285-91.
    View in: PubMed
    Score: 0.117
  18. Du T, Wang Y, Xie H, Liang D, Gao S. Fragmentation Patterns of Phenolic C-Glycosides in Mass Spectrometry Analysis. Molecules. 2024 Jun 21; 29(13).
    View in: PubMed
    Score: 0.062
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support